Identification of a Novel Class of Highly Potent, CNS-Penetrant NLRP3 Specific Inhibitors with Excellent Druglike Physical Features

Time: 3:00 pm
day: Day 1 - Track B - Afternoon

Details:

  • Learn how bioAge’s AI-driven discovery platform, based on analysis of proprietary human aging cohort data, revealed that NLRP3 levels rise with age and are positively correlated with all-cause mortality and cognitive decline
  • Discover how to identify novel NLRP3 inhibitors, BioAge screened billions of molecules in a DNA-encoded library (DEL) for compounds that bind purified NLRP3 protein. Further chemical modifications show how is possible to functionally inhibit the NLRP3 inflammasome in vivo and in vitro with comparable or superior potency relative to publicly known inhibitors
  • Review how the newly identified molecules have novel structures and chemical properties, distinct from those of publicly known NLRP3 inhibitors, with features allowing favorable oral bioavailability and BBB penetration

Speakers: